July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Subconjunctival dendrimer-drug therapy for the treatment of dry eye in rabbits with induced autoimmune dacryoadenitis
Author Affiliations & Notes
  • Hui Lin
    Wilmer Eye Institute, Johns Hopkins University, Lutherville Timonium, Maryland, United States
  • Siva Pramodh Kambhampati
    Wilmer Eye Institute, Johns Hopkins University, Lutherville Timonium, Maryland, United States
  • Chihchien Hsu
    Wilmer Eye Institute, Johns Hopkins University, Lutherville Timonium, Maryland, United States
  • Kannan Rangaramanujam
    Wilmer Eye Institute, Johns Hopkins University, Lutherville Timonium, Maryland, United States
  • Samuel C Yiu
    Wilmer Eye Institute, Johns Hopkins University, Lutherville Timonium, Maryland, United States
  • Footnotes
    Commercial Relationships   Hui Lin, None; Siva Pramodh Kambhampati, None; Chihchien Hsu, None; Kannan Rangaramanujam, None; Samuel Yiu, None
  • Footnotes
    Support  Research to Prevent Blindness to the Wilmer Eye Institute and NIH/NEI R01 1R01EY025304-01 (RMK)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4920. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hui Lin, Siva Pramodh Kambhampati, Chihchien Hsu, Kannan Rangaramanujam, Samuel C Yiu; Subconjunctival dendrimer-drug therapy for the treatment of dry eye in rabbits with induced autoimmune dacryoadenitis. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4920.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the efficacy of a single subconjunctival injection of dendrimer- dexamethasone to treat dry eye in a rabbit model of induced autoimmune dacryoadenitis (AID).

Methods : AID was induced by injecting autologous peripheral blood lymphocytes activated in a mixed cell reaction with autologous acinar cells back into the animal’s lacrimal gland (LG). Diseased animals were treated with free dexamethasone (Free-Dex), dendrimer-dexamethasone (D-Dex), or saline via a single subconjunctival injection. The clinical evaluations, including Schirmer’s test, tear breakup time (TBUT), and fluorescein and rose bengal staining, were performed. Histopathology was evaluated by H&E staining and immunostaining. Levels of inflammatory cytokines and aquaporin proteins in the LGs were determined by real-time PCR.

Results : Subconjunctivally administered dendrimers selectively localized in the inflamed LGs, and were taken up by the infiltrated cells. At two weeks post-treatment, the D-Dex group showed increased tear secretion and TBUT in comparison to diseased animals pre-treatment. No significant changes were observed in other treatment groups. On H&E staining, there was less inflammatory cell infiltration and fewer atrophic acini in D-Dex treated LGs, compared to those treated with saline or Free-Dex. Immunohistochemistry demonstrated that the intensity of CD-18 (+) and RTLA (+) was weaker in LGs in the D-Dex group than in the Free-Dex or saline-treated rabbits. Gene expression levels of IL-6, IL-8, and TNF-α were decreased in both the D-Dex and Free-Dex groups compared to the saline group, while the expression of aquaporin 4 was increased in the D-Dex group.

Conclusions : The dendrimer exhibits pathology-dependent biodistribution in the inflamed LGs. Subconjunctivally administered D-Dex suppressed LG inflammation, leading to partial recovery of LG function with clinical improvement in induced AID. Sjögren’s patients may benefit from this targeted nanomedicine approach.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×